Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QDEL - Quidel more quick diagnosis -- Ignore unavailable to you. Want to Upgrade?

To: Robert Busse who wrote (1444)	3/31/1998 3:50:00 AM
From: Mike Relyea	Read Replies (1) \| Respond to of 1693

Bob, Here's Biota's press release on Relenza: Major Milestones for Biota's Influenza Drug, Melbourne, Australia, 30 March 1998. biota.com.au Biota Holdings Limited has announced that an application to market its influenza drug, Relenza TM (zanamivir) will be filed today with the regulatory authorities in Australia.. . . . . Following completion of current Phase III trials in the United States and Europe, filings should take place in the rest of the world later this year. . . . . . Biota's stock closed significantly up on the news. The last "official" comment I heard about Quidel's flu test was made by Mr Frankel in Quidel's the 3rd quarter conference call. If I remember correctly, he said that pre-clinicals were completed. Quidel's targeting FDA approval at the same time Glaxo's Relenza is approved - hopefully 18 months from the CC in January. With all the recent news about the Hong Kong chickens, I just can't imagine Glaxo won't be getting some good press this year about Relenza's prospects. Hopefully then some smart analyst will point out Glaxo's and Quidel's test relationship. Mike